Search
eptinezumab
Indications:
- prevention of chronic migraine
- abortive therapy* for migraine [3]
* fesibility of admnistering IV infusion during migraine attack may be an issue [3]
Dosage:
- 300 mg IV infusion every 3 months
Adverse effects:
- upper respiratory infections
- sinusitis
Mechanism of action:
- humanized IgG1 monoclonal antibody
- CGRP receptor antagonist
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
calcitonin gene-related peptide (CGRP) inhibitor
pharmaceutical monoclonal antibody
References
- George J.
Eptinezumab Effective in Chronic Migraine.
Intravenous CGRP blocker shows rapid treatment effect.
MedPage Today. April 27, 2018
https://www.medpagetoday.com/meetingcoverage/aan/72586
- Lipton R, et al
A phase 3, randomized, double-blind, placebo-controlled study
to evaluate the efficacy and safety of eptinezumab for the
preventive treatment of chronic migraine: Results of the
PROMISE-2 Trial.
American Academy of Neurology (AAN) 2018.
- Lipton R, et al
Increased migraine-free intervals with eptinuzumab were
associated with improved health-related quality-of-life
outcomes through week 12: Results from the phase 3 PROMISE-1
Trial.
American Academy of Neurology (AAN) 2018.
- Egilius L et al
Repeat infusions of eptinezumab associated with greater
migraine reductions and longer migraine-free intervals:
Results from the Phase 3 PROMISE-1 Trial.
American Academy of Neurology (AAN) 2018.
- Ashina M, Saper J, Cady R et al
Eptinezumab in episodic migraine: A randomized, double-blind,
placebo-controlled study (PROMISE-1).
Cephalalgia. 2020 Mar;40(3):241-254.
PMID: 32075406 PMCID: PMC7066477 Free PMC article
- Winner PK, McAllister P, Chakhava G et al
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most
Bothersome Symptom When Initiated During a Migraine Attack. A Randomized
Clinical Trial.
JAMA. 2021;325(23):2348-2356. June 15
PMID: 34128999 PMCID: PMC8207242 (available on 2021-12-15)
https://jamanetwork.com/journals/jama/fullarticle/2781053
- Burch R, Rayhill M
Acute Treatment for Migraine. Contemporary Treatments and Future Directions.
JAMA. 2021;325(23):2346-2347. June 15
PMID: 34129013
https://jamanetwork.com/journals/jama/fullarticle/2781072